Retrospective Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. May 28, 2017; 23(20): 3702-3712
Published online May 28, 2017. doi: 10.3748/wjg.v23.i20.3702
Table 1 Patients undergoing combined liver and inferior vena cava resection
Indications for surgerynSex (M:F), nClassifications
I1H1I2H1I1H2I2H2I3H1
Hepatocellular carcinoma116:0525130
Cholangiocarcinoma2618:08310463
Colorectal metastases85:0315011
Alveolar echinococcosis95:0433021
Table 2 Intra- and postoperative results
VariablesI1H1 (n = 9)I2H1 (n = 23)I1H2 (n = 5)I2H2 (n = 12)I3H1 (n = 5)
IVC resection and replacement (n = 2)Only IVC resection (n = 3)
RL:REL:RT:LEL:LT3:2:2:1:14:6:8:2:30:1:2:2:02:4:3:2:11:0:1:0:01:2:0:0:0
Tumor size (cm)7.2 (2.9-14.3)8.7 (7.1-15.4)9.2 (3.9-9.9)9.6 (7.2-16.1)9.4 (6.6-12.2)8.3 (7.1-10.2)
Operative blood loss (mL)460 (310-950)740 (450-1250)570 (450-1050)1020 (550-1700)a680 (550-810)450 (350-560)
Need for blood transfusion180710
Transfusion volume (mL)400550 (200-950)0600 (300-850)c4000
Operation duration (min)290 (210-420)592 (480-800)520 (250-860)750 (310-1150)a580 (490-670)320 (240-440)
No. of patients using TVE22331220
No. of patients using PM5172822
Duration of TVE (min)50 (40,60)62 (46-90)48 (35-68)73 (37-89)a49 (39-57)0
Duration of PM (min)25 (10-35)36 (15-45)22.5(20-25)38 (10-50)30 (15-15)30 (15-15)
Reconstruction detailIVCR: direct suture in 4, with a patch in 5; HVR: noIVCR: replacement; HVR: noIVCR: with a patch in 5; HVR: reimplant to ePTFE in 1, to residual IVC in 4IVCR: replacement; HVR: with a patch in 3, reimplant to ePTFE in 5, to residual IVC in 4IVCR: replacement; HVR: noIVCR: no; HVR: no
Surgical technique
Anti-situm000210
Ex vivo000600
In situ perfusion021500
Postoperative liver function
Serum maximum AST (IU/L)460 (220-870)557 (240-1240)490 (230-590)630 (330-1350)520 (370,670)665 (265-768)
Serum maximum ALT (IU/L)565 (345-1350)695 (230-1510)520 (280-1020)710 (340-1405)610 (410-810)685 (210-830)
Serum maximum PT (s)14.1 (12.2-16.3)15.4 (13.3-16.9)14.8 (12.8-15.9)15.4 (13.4-17.5)16.4 (15.5-17.3)15.5 (13.7-16.7)
Serum maximum TB (mmol/L)33.4 (28.5-44.7)36.8 (29.4-56.9)33.7 (31.2-47.7)45.0 (34.1-55.6)35.0 (27.0-43.0)33.1 (28.0-56.1)
Hospital stay (d)11 (7-17)15 (9-24)12 (8-22)19 (13-28)14 (11-17)16 (13-19)
Table 3 Postoperative complications
VariableI1H1 (n = 9)I2H1 (n = 23)I1H2 (n = 5)I2H2 (n = 12)I3H1 (n = 5)
IVC resection and replacement (n = 2)Only IVC resection (n = 3)
Total number1828a21
Biliary leak111
Liver failure22
Ascites141211
Jaundice1
Hemorrhage requiring reoperation1
Thrombosis of reconstructed vessels
Hepatic vein1
Inferior vena cava1
Intraabdominal abscess1
Reconstructed vessel infection221
Wound infection
Respiratory complication11
Clavien-Dindo classification
Grade I-II172611
Grade III-V140510
90-d mortality0405a00
Table 4 Univariate analysis of factors predictive of death
All patients (n = 54)Operative death
P value
Yes (n = 9)No (n = 45)
Age (yr)49.7 (39-72)53(45-72)49 (39-67)0.249
Sex ratio (M:F)34:206:328:170.801
Preoperative chemotherapy4131.000
Preoperative PVE9271.000
Tumor type
Colorectal metastases8260.864
Hepatocellular carcinoma11291.000
Cholangiocarcinoma264221.000
Alveolar echinococcosis9181.000
Preoperative TB > 34 μmol/L6151.000
ICG-R15 over 10%9360.327
Child-Pugh B6420.004
No. of segments resected4.7 (3-6)5.1 (4-6)4.6 (4-6)0.189
Classifications0.157
I1H19090.328
I2H1234191.000
I1H25050.576
I2H212570.028
I3H15050.576
IVC replacement
Yes (I2 + 2 cases in I3)379280.044
No (I1 + 3 cases in I3)17017
Hepatic vein reconstruction
Yes (H2)174130.600
No (H1)37532
Duration of ischemia (min)68.7 (0-112)87.7 (62-112)64.9 (0-106)< 0.001
Operative blood loss (mL)721.5 (310-1250)769.0 (550-1250)712.3 (310-780)0.389
Blood transfused amount (mL)174.1 (0-950)219.4 (0-950)165.8 (0-850)0.501
Duration of operation (min)554.8 (210-1150)709.6 (310-1150)523.7 (210-860)< 0.001
R0 resection497420.401
Tumor size8.7 (2.9-16.1)9.5 (8.8-16.1)8.6 (2.9-15.4)0.062
Table 5 Multivariate binary logistic regression analysis of factors predictive of death
OR (95%CI)P value
IVC replacement37.56 (1.46-945.32)0.048
Duration of ischemia1.65 (1.02-2.58)0.005
Child B or C1.82 (1.14-2.89)0.025
Table 6 Literature review of the reported series of hepatectomies combined with inferior vena cava resection
Ref.Hospital mortalityHospital morbidityNo. alive/total (follow-up time)
DuBay et al[13]11.1% (1 of gastrointestinal bleeding and multiple organ failure)22.2%6/9 (2-33 mo)
Malde et al[15]11.4% (4 of multiple organ failure)40.0%16/35 (1-140 mo)
Azoulay et al[31]4.5% (1 of sepsis and multiple organ failure)64.0%11/22 (7-84 mo)
Madariaga et al[21]11.0% (1 of liver failure)22.2%6/9 (3-156 mo)
Giordano et al[25]4.0% (1 of liver failure)39.1%16/23 (1-33 mo)
Hemming et al[24]8.3% (liver failure and multiple organ failure)43.0%46/60 (median 31 mo)
Yamamoto[29]28.6% (1 of sepsis, 1 of liver failure)28.6%2/7 (2-72 mo)
Lodge et al[10]25% (1 of sepsis and multiple organ failure, 1 of respiratory and renal failure)87.5%7/8 (0.5-30 mo)
Table 7 Surgical technique of reported series of hepatectomies combined with inferior vena cava reconstruction
Ref.YearNo. of casesIndicationIVC repair type
Hepatic vein reconstructionVVBPerfusionTechniqueIVC reconstruction criteria
TubePatchSuture
DuBay et al[13]20099IVC leiomyosarcoma = 4; ICC = 2; PCC = 1; Metastases = 1; Malignant schwannoma = 1700Into the native IVC = 1; Into the graft = 5; Primary repair = 1Not described9In situ perfusionNot described
Malde et al[15]201135metastasis = 21; HCC = 6; ICC = 3; Other conditions = 511222Not describedNot described12In situ perfusion = 13; Anti situm = 3; Ex vivo = 6< 2 cm: direct suture; > 2 cm: with patches; > 50% of the circumference and longitudinally infiltration: replacement
Azoulay et al[31]200622Metastasis = 9; ICC =8; HCC = 2; Other cancers = 31048Into the native IVC = 4; Into the graft =2129In situ perfusion = 9; Anti situm and ex vivo = 0; TVE only = 12; Others = 1< 30% circumference: longitudinally suture; 30%-50% circumference: transversely suture; > 50% circumference: replacement
Madariaga et al[21]20009Metastasis = 1 IVC leiomyosarcoma = 3; ICC = 3; other cancers = 2801Into the graft = 1; Primary repair = 110In situ perfusion, Anti situm and ex vivo = 0; TVE only = 3Not described
Giordano et al[25]201123Metastases = 13; ICC = 3; HCC = 4; Others = 37016Into the graft = 144In situ perfusion = 4; Anti situm = 0; Ex vivo = 0< 30% of the circumference: suture; > 50% of the circumference: replacement
Hemming et al[24]201260ICC = 26; HCC = 16; Metastases = 13; Others = 538148Into the graft = 46 (ex vivo)8In situ perfusion = 8; Ex vivo = 6; Anti situm = 0< 3 cm longitudinally: end-to-end anastomosis; > 5 cm sections of the anterolateral wall: with patches; 3-8 cm longitudinally : replacement
Yamamoto[29]20127ICC = 2; HCC = 5412Into the graft = 407Anti-situm = 7> 50% of the circumference: replacement
Lodge et al[10]19998Metastasis = 8341Into the native IVC = 1; Into the graft = 36 (4 ex vivo and 2 TVE)Not describedEx vivo = 4; TVE only = 4; Anti situm = 0< 60° circumferentially and < 2 cm longitudinally: clamp tangentially